Thorough Review of Recent CBD Studies Apart from updating the literature, this article focuses on clinical studies and CBD potential interactions with other drugs.

Kerstin Iffland and Franjo Grotenhermen.Cannabis and Cannabinoid Research.Jan 2017.ahead of print http://doi.org/10.1089/can.2016.0034

 

 

Medical cannabis administration and dosing:  Suggestions are offered on cannabis-drug interactions, patient monitoring, and standards of care, while special cases for cannabis therapeutics are addressed.

MacCallum CA, Russo EB .

https://www.ncbi.nlm.nih.gov/pubmed/29307505

Indica vs. SativaDr. Russo: There are biochemically distinct strains of Cannabis, but the sativa/indica distinction as commonly applied in the lay literature is total nonsense and an exercise in futility.”

Daniele Piomelli and Ethan B. Russo.Cannabis and Cannabinoid Research.Dec 2016.ahead of print http://doi.org/10.1089/can.2015.29003.ebr

Beyond Cannabis: additional plants whose components stimulate, antagonize, or modulate different aspects of the endocannabinoid system.

Russo, Ethan. (2016). Beyond Cannabis: Plants and the Endocannabinoid System. Trends in Pharmacological Sciences. 37. 10.1016/j.tips.2016.04.005. IPS 1329

 

Entourage Effect:  phytocannabinoids, terpenes offer a pipeline of new therapeutic products.

Russo, Ethan British Journal of Pharmacology https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/j.1476-5381.2011.01238.x

Cannabidiol and Sports Performance

The aim of this narrative review was to explore various physiological and psychological effects of CBD that may be relevant to the sport and/or exercise context.

Danielle McCartney, Melissa J. Benson, Ben Desbrow, Christopher Irwin, Anastasia Suraev & Iain S. McGregor

https://sportsmedicine-open.springeropen.com/articles/10.1186/s40798-020-00251-0

 

The CB1 Receptor to Treat Body Weight Disorders

Preclinical and clinical studies that have studied the impact on body weight of various cannabinoid CB1 drugs.

Thomas Murphy  and Bernard Le Foll

https://www.mdpi.com/2218-273X/10/6/855

Therapeutic benefits of cannabis/cannabinoids, especially in the treatment of pain: evidence for various therapeutic benefits of cannabis/cannabinoids, especially in the treatment of pain, and may assist in opioid detoxification.

Baron, Eric P.  https://onlinelibrary.wiley.com/doi/pdf/10.1111/head.13345

Efficacy, safety, and costs associated with the treatment of chronic pain: After 3 months treatment, cannabis improved quality of life, reduced pain and opioid use, and lead to cost savings.

Bellnier T, Brown GW, Ortega TR. https://www.ncbi.nlm.nih.gov/pubmed/29955555

 

 

Cannabis as an Alternative to Opioids The authors found that medical cannabis laws may be associated with a reduction in the number of prescriptions filled by Medicare and Medicaid. If you look more closely at the data, you see that there are suggestions that opioid analgesics are among the drug classes that are most affected by this decline.

Daniele Piomelli, Susan Weiss, Graham Boyd, Rosalie Liccardo Pacula, and Ziva Cooper.Cannabis and Cannabinoid Research.Jul 2018.ahead of print http://doi.org/10.1089/can.2018.29011.rtl

 

 

Medical Cannabis in Patients with Chronic Pain: it can be an efficacious tool to make more effective the management of chronic pain and its consequences on functional and psychological dimension.

Poli P, Crestani F, Salvadori C, Valenti I, Sannino C. https://www.ncbi.nlm.nih.gov/pubmed/29938740

Survey of board-certified pain specialists: pain clinicians experienced in prescribing cannabis over prolonged periods view it as an effective and relatively safe treatment for chronic pain.

Sharon H, Goldway N, Goor-Aryeh I, Eisenberg E, Brill S.

https://www.ncbi.nlm.nih.gov/pubmed/30104896

 

Cannabis and Pain: A Clinical Review Cannabis is now being considered in the same way that opioids were decades ago, the combination of a drug class that is experienced as pain-relieving medications in the context of a social movement supporting the treatment for pain.

Kevin P. Hill, Matthew D. Palastro, Brian Johnson, and Joseph W. Ditre.Cannabis and Cannabinoid Research.Jan 2017.ahead of print http://doi.org/10.1089/can.2017.0017

 

Cannabis Substituted for Opioids:  Patient Self-Report Ninety-seven percent of the sample “strongly agreed/agreed” that they are able to decrease the amount of opiates they consume when they also use cannabis.

Amanda Reiman, Mark Welty, and Perry Solomon.Cannabis and Cannabinoid Research.Jan 2017.ahead of print http://doi.org/10.1089/can.2017.0012

 

Cannabinoids and spinal cord stimulation for the treatment of failed back surgery syndrome refractory pain:

The results indicate that cannabinoid agonists (THC/CBD) can have remarkable analgesic capabilities after failed back surgery.

Epifanio Mondello, Domenico Quattrone, Luigi Cardia, Giuseppe Bova, Raffaella Mallamace, Alessia A Barbagallo, Cristina Mondello, Carmen Mannucci, Martina Di Pietro, Vincenzo Arcoraci, Gioacchino Calapai https://www.dovepress.com/cannabinoids-and-spinal-cord-stimulation-for-the-treatment-of-failed-b-peer-reviewed-article-JPR

 

The Use of Cannabis for Headache Disorders There are sufficient anecdotal and preliminary results, as well as plausible neurobiological mechanisms, to warrant properly designed clinical trials.

Bryson C. Lochte, Alexander Beletsky, Nebiyou K. Samuel, and Igor Grant.Cannabis and Cannabinoid Research.Jan 2017.ahead of print http://doi.org/10.1089/can.2016.0033

 

 

 

Cannabidiol prevents pain and nerve damage in rat osteoarthritis: The data presented here indicate that local administration of CBD blocked OA pain. Prophylactic CBD treatment prevented the later development of pain and nerve damage in these OA joints.

Philpott HT, OʼBrien M, McDougall JJ. https://www.ncbi.nlm.nih.gov/pubmed/28885454

Alleviative effects of Cannabis flower on migraine and headache Treatment of headache- and migraine-related pain and the associations between different product characteristics and changes in symptom intensity following Cannabis use. Sarah S.Stith, Jegason, P.Diviant FrancoBrockelman, KeenanKeeling, BrandenHall, StorriLucern, Jacob M.Vigil https://www.sciencedirect.com/science/article/abs/pii/S2095496420300741

Cannabis as a Safer Alternative to Opioid Management of Chronic Pain

Opioid addiction has become a national public health crisis with
mortality surpassing 100,000 deaths annually due to overdose. As States have begun to
deregulate the use of cannabis and cannabis derivatives for medical purposes. Loren Nedelman https://search.proquest.com/openview/a69d6774a45ea04c630c10a84ea2cc8e/1?pq-origsite=gscholar&cbl=18750&diss=y

 

 

Cannabis use for fibromyalgia: Cannabis consumption among fibromyalgia patients in Israel is very common. Nearly all reported favorable effects on pain and sleep, and few reported adverse effects or feeling of dependence on cannabis.

Habib G, Avisar I

https://www.ncbi.nlm.nih.gov/pubmed/30140459

Cannabinoid pharmacology and therapy in gut disorders:  Cannabis has a long history for use as a remedy for symptoms related with gastrointestinal diseases.

Uranga JA, Vera G, Abalo R.

https://www.ncbi.nlm.nih.gov/pubmed/30076849

Cannabis in liver disorders: cannabidiol and Δ-tetrahydrocannabinol, have shown anti-inflammatory, antioxidant, and hepatoprotective effects.

Goyal H , Rahman MR, Perisetti A , Shah N, Chhabra R

https://europepmc.org/abstract/med/30169449

Anti-Inflammatory Activity in the colon with THCA use Inflammatory bowel diseases (IBDs) include Crohn’s disease, and ulcerative colitis. Cannabis sativa preparations have beneficial effects for IBD patients.

Rameshprabu Nallathambi, Moran Mazuz, Aurel Ion, Gopinath Selvaraj, Smadar Weininger, Marcelo Fridlender, Ahmad Nasser, Oded Sagee, Puja Kumari, Diana Nemichenizer, Maayan Mendelovitz, Nave Firstein, Orly Hanin, Fred Konikoff, Yoram Kapulnik, Timna Naftali, and Hinanit Koltai.Cannabis and Cannabinoid Research.Jan 2017.ahead of print http://doi.org/10.1089/can.2017.0027

Colorectal Cancer:  C. sativa compounds interact synergistically for cytotoxic activity against colon cancer cells and induce cell cycle arrest, apoptotic cell death, and distinct gene expression.

Rameshprabu Nallathambi, Moran Mazuz, Dvory Namdar, Michal Shik, Diana Namintzer, Ajjampura C. Vinayaka, Aurel Ion, Adi Faigenboim, Ahmad Nasser, Ido Laish, Fred M. Konikoff, and Hinanit Koltai.Cannabis and Cannabinoid Research.Jul 2018.ahead of print http://doi.org/10.1089/can.2018.0010

Cannabis link to relieving intestinal inflammation explained: Why cannabis users report that the drug reduces the symptoms of inflammatory bowel disease (IBD).

University of Massachusetts Medical School. “Cannabis link to relieving intestinal inflammation explained.” ScienceDaily. ScienceDaily, 13 August 2018. www.sciencedaily.com/releases/2018/08/180813173521.htm

Medical Marijuana and Rheumatoid Arthritis:  Medical marijuana has proven to be an effective treatment for rheumatoid arthritis.

https://www.marijuanadoctors.com/conditions/rheumatoid-arthritis/

Cannabidiol prevents pain and nerve damage in rat osteoarthritis: The data presented here indicate that local administration of CBD blocked OA pain. Prophylactic CBD treatment prevented the later development of pain and nerve damage in these OA joints.

Philpott HT, OʼBrien M, McDougall JJ. https://www.ncbi.nlm.nih.gov/pubmed/28885454

Medical Cannabis – A Source for a New Treatment for Autoimmune Disease?:

Cannabis as an immunomodulator and its potential as a new treatment option for autoimmune diseases such as diabetes type I and rheumatoid arthritis.

Katz D, Katz I, Golan A.

https://www.ncbi.nlm.nih.gov/pubmed/27215114

 

Self-reported cannabis use and biomarkers of inflammation among adults in the United States

Self-reported cannabis use, particularly cannabis use within the past 30 days, was associated with lower levels of each biomarker of systemic inflammation

Chukwuemeka N. Okafor, Michael Li, Jason Paltzer

https://www.sciencedirect.com/science/article/pii/S2666354620300740

 

A Systematic Review With Meta-Analysis of the Efficacy of Cannabis and Cannabinoids for Inflammatory Bowel Disease

Cannabi(noid)s do not induce clinical remission or affect inflammation in IBD patients. However, cannabi(noid)s significantly improve patient-reported symptoms and QoL.

Doeve, Benthe H. MD; van de Meeberg, Maartje M. MD; van Schaik, Fiona D.M. MD, PhD; Fidder, Herma H. MD, PhD

https://journals.lww.com/jcge/Abstract/9000/A_Systematic_Review_With_Meta_Analysis_of_the.97574.aspx

CBD and PTSD:  recent studies have confirmed the ability of CBD to alter important aspects of aversive memories in humans and promote significant improvements in the symptomatology of PTSD.

Bitencourt RM, Takahashi RN https://www.ncbi.nlm.nih.gov/pubmed/30087591

Veterans using Cannabis Medically versus Recreationally:  Veterans who use cannabis for medicinal purposes differ significantly in sleep, physical and mental health functioning than veterans who use cannabis for recreational purposes.

Metrik J, Bassett SS, Aston ER, Jackson KM, Borsari B https://www.ncbi.nlm.nih.gov/pubmed/30003119

Cannabis and Cannabinoids in the threatment of PTSD: the effects of cannabis and cannabinoids in PTSD and the preclinical and clinical literature on the effects of cannabinoids and endogenous cannabinoid signaling systems.

Hill MN, Campolongo P, Yehuda R, Patel S. https://www.ncbi.nlm.nih.gov/pubmed/28745306

CBD’s ability to reduce fear memories and drug memories (substance abuse) : Understanding how cannabidiol regulates emotion and emotional memory processing may eventually lead to its use as a treatment for anxiety-related and substance abuse disorders.

Lee JLC, Bertoglio LJ, Guimarães FS, Stevenson CW https://www.ncbi.nlm.nih.gov/pubmed/28268256

A user’s guide to cannabinoid therapies in oncology: Patients with malignant disease, at all points of their disease trajectory, could be candidates for cannabinoid therapies whether as monotherapies or as adjuvants.

Maida V, Daeninck PJ. https://www.ncbi.nlm.nih.gov/pubmed/28050136

Cannabinoids for Symptom Management and Cancer Therapy: Pain, nausea, anti-cancer potential of cannabis.

Davis, MP

https://www.ncbi.nlm.nih.gov/pubmed/27407130

Colorectal Cancer:  C. sativa compounds interact synergistically for cytotoxic activity against colon cancer cells and induce cell cycle arrest, apoptotic cell death, and distinct gene expression.

Rameshprabu Nallathambi, Moran Mazuz, Dvory Namdar, Michal Shik, Diana Namintzer, Ajjampura C. Vinayaka, Aurel Ion, Adi Faigenboim, Ahmad Nasser, Ido Laish, Fred M. Konikoff, and Hinanit Koltai.Cannabis and Cannabinoid Research.Jul 2018.ahead of print http://doi.org/10.1089/can.2018.0010

Cannabinoid Regulation of Acute and Anticipatory Nausea: Pre-clinical evidence points to a compelling need to evaluate the antinausea potential of cannabidiol, cannabidiolic acid, and related treatments.

Rock EM, Sticht MA, Limebeer CL, Parker LA.

https://www.ncbi.nlm.nih.gov/pubmed/28861486

Cannabidiol-induced apoptosis in human colorectal cancer cells: CBD treatment in vivo, confirming its role as a novel, reliable anticancer drug.

Soyeon Jeong, Hye Kyeong Yun, Yoon A.Jeong, Min Jee Jo, Sang Hee Kang, Jung Lim Kim, Dae Yeong Kim, Seong Hye Park, Bo Ram Kima Yoo Jin Na, Sun Il Lee, Han Do Kim, Dae Hyun Kim, Sang Cheul Oh, Dae-Hee Lee https://www.sciencedirect.com/science/article/pii/S0304383519300230

Cannabis_Oil_CancerSafety and effectiveness of medical cannabis as a complementary option for supportive cancer care:

The Cannabis Pilot Project (CPP) was implemented at the Cedars Cancer Centre of the McGill University Health Centre to evaluate MC as a complementary option for symptom control in SCC.

Antonio Vigano, Saro Aprikian, Popi Kasvis, Virginie Bacis, Amna Al Harrasi, Nathalie M Aubin https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.12106

 

Cannabinoid Effects on Experimental Colorectal Cancer Models Reduce Aberrant Crypt Foci (ACF) and Tumor Volume: A Systematic Review

Cannabinoids might be substances with possible therapeutic potential for cancer because they can attenuate the side effects of chemotherapy and have antiproliferative and antimetastatic effects.

Eduardo Orrego-González, Luisa Londoño-Tobón, José Ardila-González, Diego Polania-Tovar, Ana Valencia-Cárdenas, and Alberto Velez-Van Meerbeke

https://www.hindawi.com/journals/ecam/2020/2371527

The management of anorexia and weight loss in AIDS and cancer: Dronabinol exerts its effects by directly acting on the vomiting and appetite control centers in the brain, which in turn increases appetite and prevents vomiting.

Badowski ME, Yanful PK. https://www.ncbi.nlm.nih.gov/pubmed/29670357

HCV–HIV co-infected patients with progression of hepatic fibrosis:Marijuana use did not increase the prevalence or progression of hepatic fibrosis in HCV and HCV–HIV-coinfected patients.

Farooqui, Muhammad T.; Khan, Muhammad Ali; Cholankeril, George; Khan, Zubair; Mohammed Abdul, Mubeen K.; Li, Andrew A.; Shah, Neha; Wu, Lin; Haq, Khwaja; Solanki, Shantanu; Kim, Donghee; Ahmed, Aijaz https://journals.lww.com/eurojgh/Abstract/publishahead/Marijuana_is_not_associated_with_progression_of.97965.aspx

Therapeutic use of medicinal cannabis in difficult to manage epilepsy:

Lawson JA, Scheffer IE.

Large review of Epilepsy Studies: cannabinoids as adjunctive treatments for treatment-resistant epilepsy.

Stockings E, Zagic D, Campbell G, Weier M, Hall WD, Nielsen S, Herkes GK, Farrell M, Degenhardt L.

https://www.ncbi.nlm.nih.gov/pubmed/29511052

CBD for treatment of autism spectrum disorder:

available pre-clinical and clinical data regarding the safety and effectiveness of medical cannabis, including CBD, in young ASD patients.

Poleg S, Golubchik P, Offen D, Weizman A

https://www.ncbi.nlm.nih.gov/pubmed/30171992

Practical Experiences using CBD for Epilepsy: with concomitant use of clobazam and interactions for seizure reduction.

Porcari GS, Fu C, Doll ED, Carter EG, Carson RP.

https://www.ncbi.nlm.nih.gov/pubmed/29429908

CBD in the Treatment of Refractory Epilepsy: Results suggest that adding CBD to the treatment of patients with refractory epilepsy may result in a significant reduction in seizure frequency.

Hausman-Kedem M, Menascu S, Kramer U.

https://www.ncbi.nlm.nih.gov/pubmed/29674131

The completion of three high-quality placebo-controlled adjunctive-therapy trials: There is now class 1 evidence that adjunctive use of CBD improves seizure control in patients with specific epilepsy syndromes.

 

 

Perucca E.

https://www.ncbi.nlm.nih.gov/pubmed/29344464

Cannabidiol Study on Dravet Syndrome: Results provide critical preclinical evidence supporting treatment of epilepsy and autistic-like behaviors linked to DS with CBD.

Kaplan JS, Stella N, Catterall WA, Westenbroek RE.

https://www.ncbi.nlm.nih.gov/pubmed/28973916

CBD in Treatment-Resistant Epilepsy: investigated if there is any difference in efficacy between CBD-rich extracts compared to purified CBD products.

Pamplona FA, da Silva LR, Coan AC. https://www.ncbi.nlm.nih.gov/pubmed/30258398

Correction of Autism-Related Social Impairment: the endocannabinoid anandamide mediates the action of oxytocin, a neuropeptide that is crucial for social behavior, to control social reward. Oxytocin signaling has been implicated in autism spectrum disorder.

Wei D, Dinh D, Lee D, Li D, Anguren A, Moreno-Sanz G, Gall CM, Piomelli D.

https://www.ncbi.nlm.nih.gov/pubmed/28861483

 

 

Cannabidiol or CBD Oil: Help, Hope, and Hype for Psychiatric and Neurologic Conditions

This article presents proven, promising, and potential therapeutic uses for cannabidiol (CBD) in the treatment of psychiatric and neurologic conditions and diseases.

https://journals.sagepub.com/doi/10.1177/1078390320929410

 

 

 

Medical cannabis preparation in a monocentric series of young patients with drug resistant epilepsy

The present study, although with some limitations, shows a good safety profile of medical cannabis in children and young patients with drug-resistant epilepsy and encourages the possibility of further studies with oral cannabis-based drugs.

MarcellaGherzi, GiuliaMilano, CarmenFucile, Maria GraziaCalevo, Maria MargheritaMancardi, LinoNobili, PietroAstuni, ValeriaMarini, SebastianoBarco, GiulianaCangemi, LucaManfredini, FrancescaMattioli, ElisaDe Grandis

https://www.sciencedirect.com/science/article/abs/pii/S0965229919316012?via%3Dihub

Cannabidiol-enriched oil in children and adults with treatment-resistant epilepsy-does tolerance exist?

To evaluate the long-term effectiveness of cannabidiol (CBD)-enriched oil for the treatment of refractory epilepsy and to assess the development of tolerance to its anti-seizure effect.

Shimrit Uliel-Sibony, Moran Hausman-Kedem, Aviva Fattal-Valevski, Uri Kramer

Cannabinoids for People with ASD: A Systematic Review of Published and Ongoing Studies

Among other biological hypotheses, researchers have evidenced an imbalance in the endocannabinoid (eCB) system, which regulates some functions typically impaired in ASD, such as emotional responses and social interaction.

Laura Fusar-Poli, Vito Cavone, Silvia Tinacci, Ilaria Concas, Antonino Petralia, Maria Salvina Signorelli, Covadonga M. Díaz-Caneja, Eugenio Aguglia

https://www.preprints.org/manuscript/202007.0373/v1

CARE-E) study: a phase 1 dosage escalation study: A trial of CBD in children with treatment-resistant epileptic encephalopathy.

Reithmeier D, Tang-Wai R, Seifert B, Lyon AW, Alcorn J, Acton B, Corley S, Prosser-Loose E, Mousseau DD, Lim HJ, Tellez-Zenteno J, Huh L, Leung E, Carmant L, Huntsman RJ.

https://www.ncbi.nlm.nih.gov/pubmed/29981580

CBD for treatment of autism spectrum disorder:

available pre-clinical and clinical data regarding the safety and effectiveness of medical cannabis, including CBD, in young ASD patients.

Poleg S, Golubchik P, Offen D, Weizman A

https://www.ncbi.nlm.nih.gov/pubmed/30171992

Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder: Following the cannabis treatment, behavioral outbreaks were much improved or very much improved in 61% of patients.

Adi Aran, Hanoch Cassuto, Asael Lubotzky, Nadia Wattad, Esther Hazan https://link.springer.com/article/10.1007/s10803-018-3808-2

Marijuana Use in Pregnancy and While Breastfeeding:

Marijuana use may be associated with growth restriction, stillbirth, spontaneous preterm birth, and neonatal intensive care unit admission.

Metz TD, Borgelt LM. https://www.ncbi.nlm.nih.gov/pubmed/30234728

Review of the Science in developmental-behavioral pediatrics: Risks and benefits for the proposed uses of cannabis in developmental and behavioral conditions, including attention-deficit hyperactivity disorder and autism spectrum disorder.

Hadland SE, Knight JR, Harris SK.

https://www.ncbi.nlm.nih.gov/pubmed/25650954

Parkinson’s and other Neuronal Diseases: the structure-activity relationship (SAR) of cannabinoid compounds able to bind to cannabinoid receptors and act as therapeutic agents in neuronal diseases.

Prandi C, Blangetti M, Namdar D, Koltai H.

https://www.ncbi.nlm.nih.gov/pubmed/29941830

Neuroprotection by Cannabinoids in Huntington’s Disease: experimental evidence showed researchers that CBD aid neurons with its antioxidant properties.

Hospital Universitario Ramón y Cajal https://clinicaltrials.gov/ct2/show/NCT01502046

Effects of cannabidiol in Alzheimer’s disease: CBD suppresses, through activation of PPARγ, pro-inflammatory signaling and may be a potential new candidate for Alzheimer’s disease therapy.

 

Vallée A, Lecarpentier Y, Guillevin R, Vallée JN https://www.ncbi.nlm.nih.gov/pubmed/28981597

Parkinson’s, Dyskinesia and Movement Disorders: cannabidiol emerges as a promising compound to treat and/or prevent movement disorders.

Peres FF, Lima AC, Hallak JEC, Crippa JA, Silva RH, Abílio VC.

https://www.ncbi.nlm.nih.gov/pubmed/29867488

Chronic Neuropathic Pain: THC significantly reduced patients’ pain compared to placebo. THC-induced analgesia was correlated with a reduction in functional connectivity between the anterior cingulate cortex (ACC) and the sensorimotor cortex.

Libat Weizman, Lior Dayan, Silviu Brill, Hadas Nahman-Averbuch, Talma Hendler, Giris Jacob, Haggai Sharon http://n.neurology.org/content/early/2018/09/05/WNL.0000000000006293

Medicinal Cannabinoids in Patients With Multiple Sclerosis: efficacy of cannabinoids for the treatment of spasticity, pain, and bladder dysfunction in patients with MS.

Mari Carmen Torres-Moreno, PhDEsther Papaseit, MD, PhDMarta Torrens, MD, PhD

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2706499

THC\CBD oromucosal spray  for treating resistant multiple sclerosis spasticity: significantly more effective than readjusting standard antispasticity therapy and provided new evidence of efficacy.

Jolana Marková https://www.futuremedicine.com/doi/full/10.2217/nmt-2018-0050

Cannabinoid receptor as a potential therapeutic target for Parkinson’s Disease:  the role of cannabinoid receptors (CBRs) in curtailing the progression of PD by activating neuroprotective pathways.

Himadri Shekhaar Baul, Ceera Manikandan, Dwaipayan Sen https://www.futuremedicine.com/doi/full/10.2217/nmt-2018-0050

Cannabinoids in multiple sclerosis: A neurophysiological analysis

To investigate the action of cannabinoids on spasticity and pain in secondary progressive multiple sclerosis, by means of neurophysiological indexes.

Domizia Vecchio, Claudia Varrasi, Eleonora Virgilio, Antonio Spagarino, Paola Naldi, Roberto Cantello

Medical Marijuana for Depression, Bipolar Disorder and Anxiety:  unlike medical marijuana for chronic, debilitating pain, there’s a lot of additional factors that must be taken into account when studying mental illness and a psychoactive substance like marijuana.

John M. Grohol, Psy.D. https://psychcentral.com/blog/medical-marijuana-for-depression-bipolar-disorder-anxiety-mental-illness-can-it-help/

Medical Marijuana for Psychiatric Disorders: clinicians can feel increasingly comfortable utilizing this medication for very specific psychiatric disorders.

Jeremy Spiegel M.D. https://www.psychologytoday.com/us/blog/mind-tapas/201303/medical-marijuana-psychiatric-disorders

Biphasic effects of THC in memory and cognition: THC paradoxically promotes hippocampal neurogenesis, prevents neurodegenerative processes occurring in animal models of Alzheimer’s disease.

Calabrese EJ, Rubio-Casillas A  https://www.ncbi.nlm.nih.gov/pubmed/29574698

CBD’s ability to reduce fear memories and drug memories (substance abuse) : Understanding how cannabidiol regulates emotion and emotional memory processing may eventually lead to its use as a treatment for anxiety-related and substance abuse disorders.

Lee JLC, Bertoglio LJ, Guimarães FS, Stevenson CW https://www.ncbi.nlm.nih.gov/pubmed/28268256

Marijuana use by middle-aged and older adults: Marijuana use is becoming more prevalent in this population and users are also at high risk for other drug use.

Han BH, Palamar JJ https://www.ncbi.nlm.nih.gov/pubmed/30197051

 

The antidepressant effect of cannabidiol: recent evidence suggests that CBD promotes both a rapid and a sustained antidepressant effect.

Silote, Gabriela, Sartim, Ariandra Guerini, Sales, Amanda J Eskelund, Amanda, Guimarães, Francisco S,  Wegener, Gregers,  Joca, Sâmia

http://www.forskningsdatabasen.dk/en/catalog/2443061455

 

Effectiveness of Raw, Natural Medical Cannabis Flower for Treating Insomnia:

Consumption of medical Cannabis flower is associated with significant improvements in perceived insomnia.

Vigil JM, Stith SS, Diviant JP, Brockelman F, Keeling K, Hall B https://www.ncbi.nlm.nih.gov/pubmed/29997343

 

Cannabis, Cannabinoids, and Sleep: Preliminary research into cannabis and insomnia suggests that cannabidiol (CBD) may have therapeutic potential for the treatment of insomnia.

Babson KA, Sottile J, Morabito D. https://www.ncbi.nlm.nih.gov/pubmed/28349316

With more approved conditions per capita, no wonder seniors are the fastest growing demographic in the use of cannabis for medical use.

As of last year, Autism is now an approved condition in Colorado as an alternative treatment option.

Flow with Fountain and Follow us on Social Media!